Clinical Trial Update: A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) [Phase 3]

View source ↗

Summary

A Phase 3 trial (Measure Up 2) evaluating Upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis has completed and results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2022-03-28